Jonathan W. Goldman MD and David R Spigel MD; ASCO 2026: Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results

Jonathan W. Goldman MD and David R Spigel MD; ASCO 2026: Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results

June 23, 2026 · 10 min

About this episode

The episode discusses the benefits of Selpercatinib for patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer based on early results from the LIBRETTO-432 trial.

Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results An interview with: Jonathan W. Goldman MD, Director of Clinical Trials i

People in this episode

Guests: Jonathan W. Goldman MD, David R Spigel MD

Topics covered

Keywords

Mentioned in this episode

Organizations: ASCO

Products: Selpercatinib

Places: Non-Small Cell Lung Cancer

More episodes of Audio Journal of Oncology Podcast

Explore listener stats, chart rankings, contacts and more on the Audio Journal of Oncology Podcast podcast page.